|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Here, we provide our perspective on how to improve the success of CAR T therapy in solid tumors by focusing on the aspects of target selection and the related TME in CAR T cell design, especially stressing the interplay between them.
|
30906625 |
2019 |
|
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
These works confirmed that simultaneous use of cytokines, for example, rhIL-12, can increase the anti-tumor activity of CAR-T cells, especially for treatments of several types of solid tumors.
|
31237116 |
2019 |
|
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Here, we reviewed the solid tumor CAR-T clinical trials, emphasizing the studies with published results.
|
29433552 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Infiltration, accumulation, and survival of chimeric antigen receptor T (CAR-T) cells in solid tumors is crucial for tumor clearance.
|
29505028 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Specifically, this review covered the following areas: (1) the current status of CAR-T cells in the treatment of solid tumors; (2) the major factors constraining the efficacy of CAR-T cells in solid tumors; and (3) opinions regarding the future of CAR-T as a treatment for solid tumors.
|
29048935 |
2017 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CAR T-cell Therapy for Solid Tumors?
|
30291124 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, the performance of CAR-T cell treatment in solid tumor is not as satisfactory as that in hematologic disease.
|
29769134 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Researchers increased the effectiveness of CAR T-cell therapy in solid tumors by injecting the cells near the tumors.
|
25583818 |
2015 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Combining CAR-T or CAR-NK cells with chemotherapeutic drugs to treat solid tumor may be a promising strategy.
|
29423418 |
2017 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Although CAR-T cell therapy did not have satisfactory responses in solid tumors, researchers were still holding an optimistic attitude towards its future efficacy with more modifications of its structure.
|
30886654 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CAR-T cell therapy has achieved gratifying breakthrough in hematological malignancies and promising outcome in solid tumor as showed in various clinical trials.
|
28356156 |
2017 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Identifying targets for chimeric antigen receptor-modulated T lymphocyte (CAR-T) therapy against solid tumors is an urgent problem to solve.
|
29935762 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The presence of sCAR in MPE puts forward the notion that in certain contexts (e.g., within the extracellular matrix of solid tumors) the concentrations of secreted (or shed) CAR may be high enough to effectively compete with Ad gene delivery.
|
12060636 |
2002 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The data confirmed the antitumor ability and safety of CAR-T cells targeting EpCAM and may provide a new target for CAR-T cell therapies in treating solid tumors.
|
30693795 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
New regimens, including combinations with chemical drugs, need to be studied to enhance the therapeutic efficacy of CAR-T or NK cells for solid tumors.
|
30410941 |
2018 |
|
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Our results guide new therapeutic options for GD2.CAR-Ts in patients with neuroblastoma, and CAR-T development for a broad range of solid tumors.
|
30617136 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Chimeric antigen receptor T (CAR-T) cells have shown promising efficacy in treatment of hematological malignancies, but its applications in solid tumors need further exploration.
|
28366766 |
2017 |
|
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, we will discuss extrinsic factors that can be manipulated to influence CAR-T performance such as choice of cellular population, culturing conditions and additional modifications that enhance their activity particularly in solid tumors.
|
26797495 |
2016 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, due to the lack of ideal tumor surface antigens, CAR-T cell therapy has limited success in treating solid tumors.
|
31597088 |
2019 |
|
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Metabolic regulation of CAR T cell function by the hypoxic microenvironment in solid tumors.
|
30678555 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors.
|
30636882 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Analysis of Antitumor Effects of CAR-T Cells in Mice with Solid Tumors.
|
31707682 |
2020 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The tumor vasculature an attractive CAR T cell target in solid tumors.
|
31628559 |
2019 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The obstacles that reduce the efficacy of CAR-T therapy in solid tumors include a lack of specific tumor antigens, limited trafficking and penetration of CAR-T cells to tumor sites, and an immunosuppressive tumor microenvironment.
|
29861325 |
2018 |
|
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
There are obvious differences between the two countries in CAR-targeted antigens in solid tumors and genetic modifications besides CARs for enhancing the potency of CAR T-cells.
|
30307029 |
2019 |